Volume 23, Number 5—May 2017
Research
Lack of Durable Cross-Neutralizing Antibodies Against Zika Virus from Dengue Virus Infection
Matthew H. Collins
, Eileen McGowan, Ramesh Jadi, Ellen Young, Cesar A. Lopez, Ralph S. Baric, Helen M. Lazear, and Aravinda M. de Silva
, Eileen McGowan, Ramesh Jadi, Ellen Young, Cesar A. Lopez, Ralph S. Baric, Helen M. Lazear, and Aravinda M. de Silva
Table 3
50% Inhibitory concentrations for serum in depletion experiments of DENV and Zika virus*
| Serum sample ID |
DENV-2 |
DENV-4 |
Zika virus |
| DT000 | |||
| Control | 744 | 612 | 29 |
| Depleted |
<20 |
<20 |
<20 |
| DT001 | |||
| Control | 1,376 | 60 | <20 |
| Depleted |
331 |
24 |
<20 |
| DT168 | |||
| Control | 83 | 48 | 1,978 |
| Depleted |
<20 |
<20 |
2,351 |
| DT172 | |||
| Control | 22 | 32 | 2,341 |
| Depleted |
<20 |
<20 |
2,046 |
| DT165 | |||
| Control | 198 | 162 | 3,067 |
| Depleted |
31 |
78 |
2,060 |
| DT166 | |||
| Control | 1,556 | 1,138 | 1,090 |
| Depleted | <20 | 126 | 873 |
*DENV, dengue virus; ID, identification. Specific antibodies were depleted using beads coated with DENV1 and DENV2 antigens. Beads coated with BSA were used as a control.
Page created: April 14, 2017
Page updated: April 14, 2017
Page reviewed: April 14, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.